Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 4/20 | 0.43 |
| ▸ | CA12 | O43570 | 4/20 | 0.42 |
| ▸ | CA1 | P00915 | 4/20 | 0.42 |
| ▸ | CA9 | Q16790 | 4/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9191743 | 0.82 | CYP3A4 (0.45) | CYP3A4TSHRTRPA1MAPK1TDP1 | |
| SCHEMBL6763899 | 0.79 | PREP (0.53) | PREPCA12CA1CA9 | |
| SCHEMBL17029133 | 0.78 | CA12 (0.35) | PREPCA12CA1CA9CYP3A4 | |
| SCHEMBL4106972 | 0.76 | CYP3A4 (0.49) | CYP3A4TSHRTRPA1MAPK1TDP1 | |
| SCHEMBL29396829 | 0.75 | CA12 (0.43) | PREPCA12CA1CA9CYP3A4 | |
| SCHEMBL3148700 | 0.74 | CYP3A4 (0.45) | CYP3A4TSHRTRPA1MAPK1TDP1 | |
| SCHEMBL18107549 | 0.74 | CYP3A4 (0.45) | CYP3A4TSHRTRPA1MAPK1TDP1 | |
| SCHEMBL29183508 | 0.74 | PPARA (0.43) | PREPCA12CA1CA9TSHR | |
| SCHEMBL29394688 | 0.73 | CA12 (0.41) | PREPCA12CA1CA9CYP3A4 | |
| SCHEMBL23491348 | 0.73 | PREP (0.57) | PREPCA12CA1CA9CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230089368-A1 | POLYAROMATIC UREA DERIVATIVES AND THEIR USE IN THE TREATMENT OF MUSCLE DISEASES | ANAGENESIS BIOTECHNOLOGIES S.A.S. (FR) | 2023-03-23 | — | — | US | disclosed |
| EP-4029501-A1 | COMBINATION OF POLYAROMATIC UREA DERIVATIVES AND GLUCOCORTICOID OR HDAC INHIBITOR FOR THE TREATMENT OF DISEASES OR CONDITIONS ASSOCIATED WITH MUSCLE CELLS AND/OR SATELLITE CELLS | Anagenesis Biotechnologies (FR) | 2022-07-20 | — | — | EP | disclosed |
| EP-3999057-A1 | POLYAROMATIC UREA DERIVATIVES AND THEIR USE IN THE TREATMENT OF MUSCLE DISEASES | ANAGENESIS BIOTECHNOLOGIES SAS (FR) | 2022-05-25 | — | — | EP | disclosed |
| CN-114144410-A | Polyarylurea derivatives and their use in the treatment of muscular diseases | 阿纳格纳斯生物技术股份有限公司 | 2022-03-04 | — | — | CN | disclosed |
| WO-2021013712-A1 | POLYAROMATIC UREA DERIVATIVES AND THEIR USE IN THE TREATMENT OF MUSCLE DISEASES | ANAGENESIS BIOTECHNOLOGIES S.A.S. (FR) | 2021-01-28 | — | — | WO | disclosed |
| US-8252841-B2 | Methods of inhibiting bacterial virulence and compounds relating thereto | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-08-28 | — | — | US | disclosed |
| US-20100048573-A1 | Methods of Inhibiting Bacterial Virulence and Compounds Relating Thereto | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2010-02-25 | — | — | US | disclosed |
| WO-1999064041-A9 | MULTIBINDING AGENTS THAT MODULATE NMDA RECEPTORS | ADVANCED MEDICINE INC (US) | 2001-05-31 | — | — | WO | disclosed |
| EP-1100519-A1 | MULTIBINDING AGENTS THAT MODULATE NMDA RECEPTORS | Advanced Medicine, Inc. (US) | 2001-05-23 | — | — | EP | disclosed |
| WO-1999064041-A1 | MULTIBINDING AGENTS THAT MODULATE NMDA RECEPTORS | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230089368-A1 | POLYAROMATIC UREA DERIVATIVES AND THEIR USE IN THE TREATMENT OF MUSCLE DISEASES | CKMT1A; CKMT1B, TNNC1, UBQLN2 | PREP 1461/4885CA12 4534/4885CA1 4765/4885 |
| US-20100048573-A1 | Methods of Inhibiting Bacterial Virulence and Compounds Relating Thereto | MMP8, SLC11A2, NFKBIA | PREP 292/4885CA12 4360/4885CA1 4431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.